PPT-Diagnosis, Prevention and Management of Statin Adverse Effects and Intolerance:

Diagnosis Prevention and Management of Statin Adverse Effects and Intolerance Canadian Consensus Working Group Update 2016 GB John Mancini MD Steven Baker MD Jean Bergeron MD David Fitchett MD. Anticoagulant, Antiplatelet, and Thrombolytic Drugs. Physiology and Pathophysiology of Coagulation. Hemostasis. Stage 1:. . formation of platelet plug. Platelet aggregation. Stage 2:. . coagulation. 2. Learning Objectives. Upon completion of this content, the learner will be able to. Describe the epidemiology of PID in the U.S.;. Describe the pathogenesis of PID. ;. Discuss the clinical manifestations of PID;. Presentation to HL7 Patient Care WG . Draft Recommendations for Canadian Standards (being discussed). NB: HL7 . meeting discussion notes are included on slide 21. . Post meeting notes from . Russell B. Leftwich, M.D.,  . Teaching Aims. You will learn all about adverse donor reaction and prevention of certain reactions. . You will learn to define, identify/diagnose and handle all the reactions.. Adverse Donor Reactions. Canadian Consensus . Working Group Update (2016). G.B. John Mancini, MD, Steven Baker, MD, Jean Bergeron, MD, David Fitchett, MD, . Jiri Frohlich, MD, Jacques Genest, MD, Milan Gupta, MD, Robert A. Hegele, MD, . 2. Learning Objectives. Upon completion of this content, the learner will be able to. Describe the epidemiology of PID in the U.S.;. Describe the pathogenesis of PID. ;. Discuss the clinical manifestations of PID;. James J. Lehman, DC, MBA, FACO. Associate Professor of Clinical Sciences. School of Chiropractic. Director. Community Health Clinical Education. University of Bridgeport. Learning Objectives. . Organize a clinical thought process while performing a neuromusculoskeletal evaluation of a patient with statin myopathy and piriformis syndrome.. Purpose. Outline highlights from the 2018 ACC/AHA Guideline on the Management of Blood Cholesterol. Review statin management in high risk patients. 2. ACC/AHA 2018: Overall Approach. Assess risk, determine management group. Control. Relative risk. Absolute Effect. (per thousand). Statin. Myalgia. 348/14960. (2.3%) . 288/14520. (2.0%). 1.02. (0.88-1.19). +1. (-1 to +5). Rhabdomyolysis. 138/2454. (5.6%). 158/2446. (6.5%). . Rabizadeh. , . MD. .. Imam . Khomeini . Medical . Complex,. Tehran . University of Medical Sciences. Introduction. Statin . use has . increased progressively in all age groups since . 1988 . The . PRESENTER: NWANKWO HELEN. RN/RM,BSCPH, MPH candidate. University of Rwanda, SONM . Learning Objectives. . Describe the appropriate timing of IUCD insertion. State the steps for IUCD insertion and removal. to Reduce Atherosclerotic Cardiovascular . Risk in Adults . 2013 ACC/AHA Guideline on. O. verview. RCTs indicated a constant reduction of ASCVD by . statins. in 1ry & 2ry prevention.. No event reduction. Alfred Fisher MD PhD. Professor and Chief. Division of Geriatrics, Gerontology,. and Palliative Medicine. University of Nebraska Medical Center. Older Patients in Primary Care often take Statins. Johansen, et. al. . Food intolerance. Most people can eat foods without any problems although they may have different likes or dislikes that influence what they choose. . However, some people react to certain foods and eating them may cause uncomfortable symptoms or,...